- Home
- HIO vs DCTH Comparison
HIO vs DCTH Comparison
Compare HIO & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HIO
- DCTH
- Stock Information
- Founded
- HIO 1993
- DCTH 1988
- Country
- HIO United States
- DCTH United States
- Employees
- HIO N/A
- DCTH N/A
- Industry
- HIO Finance/Investors Services
- DCTH Medical/Dental Instruments
- Sector
- HIO Finance
- DCTH Health Care
- Exchange
- HIO Nasdaq
- DCTH Nasdaq
- Market Cap
- HIO 368.0M
- DCTH 388.3M
- IPO Year
- HIO N/A
- DCTH N/A
- Fundamental
- Price
- HIO $3.86
- DCTH $9.83
- Analyst Decision
- HIO
- DCTH Strong Buy
- Analyst Count
- HIO 0
- DCTH 4
- Target Price
- HIO N/A
- DCTH $24.25
- AVG Volume (30 Days)
- HIO 305.3K
- DCTH 1.1M
- Earning Date
- HIO 01-01-0001
- DCTH 11-04-2025
- Dividend Yield
- HIO 10.33%
- DCTH N/A
- EPS Growth
- HIO N/A
- DCTH N/A
- EPS
- HIO N/A
- DCTH 0.06
- Revenue
- HIO N/A
- DCTH $70,240,000.00
- Revenue This Year
- HIO N/A
- DCTH $146.50
- Revenue Next Year
- HIO N/A
- DCTH $37.19
- P/E Ratio
- HIO N/A
- DCTH $175.70
- Revenue Growth
- HIO N/A
- DCTH 491.35
- 52 Week Low
- HIO $3.52
- DCTH $8.87
- 52 Week High
- HIO $4.03
- DCTH $18.23
- Technical
- Relative Strength Index (RSI)
- HIO 50.33
- DCTH 40.06
- Support Level
- HIO $3.81
- DCTH $9.15
- Resistance Level
- HIO $3.88
- DCTH $12.70
- Average True Range (ATR)
- HIO 0.04
- DCTH 0.73
- MACD
- HIO 0.01
- DCTH -0.17
- Stochastic Oscillator
- HIO 76.92
- DCTH 19.16
About HIO Western Asset High Income Opportunity Fund Inc.
Western Asset High Income Oppor Fd Inc is a diversified closed-end management investment company. The company's primary objective is to seek high current income and the secondary objective is capital appreciation. It invests a majority of its net assets in high-yield corporate debt securities and the rest in common stock equivalents, including options, warrants, and rights. The company invests in securities of companies from various sectors such as energy, technology, utilities, industrials, communications, finance, and capital goods among others.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.